Influence of particle size and material properties on mucociliary clearance from the airways

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 4, 2010, Pages 233-241

  Henning, Andreas ^a,b   Schneider, Marc ^b   Nafee, Noha ^b,c   Muijs, Leon ^b   Rytting, Erik ^d   Wang, Xiaoying ^d   Kissel, Thomas ^d   Grafahrend, Dirk ^e   Klee, Doris ^e   Lehr, Claus Michael ^b  

^a Johns Hopkins University   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c Alexandria University Faculty of Pharmacy   (Egypt)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

airways; inhalation therapy; Mucociliary clearance; nanoparticles, mucus

Indexed keywords

COPOLYMER; MACROGOL; NANOPARTICLE; POLYGLACTIN; POLYSTYRENE;

ARTICLE; DRUG DELIVERY SYSTEM; LUNG CLEARANCE; MUCOADHESION; MUCOCILIARY CLEARANCE; MUCUS; PARTICLE SIZE; TRACHEA; ZETA POTENTIAL;

ANIMALS; CHICK EMBRYO; MUCOCILIARY CLEARANCE; NANOPARTICLES; PARTICLE SIZE; PARTICULATE MATTER; POLYMERS; RESPIRATORY SYSTEM; TRACHEA;

EID: 77955437973     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0806     Document Type: Article

References (61)

1. Gehr P, Bachofen M, and Weibel ER: The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol. 1978;32:121-140.
2. Corkery K: Inhalable drugs for systemic therapy. Respir Care. 2000;45:831-835.
3. Patton JS, Fishburn CS, and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1:338-344.
4. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, and Guyatt G: Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians=American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-371.
5. Knowles MR, and Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109:571-577.
6. Wanner A, Salathe M, and ORiordan TG: Mucociliary clearance in the airways. Am J Respir Crit Care Med. 1996;154:1868-1902.
7. Gehr P, Green FHY, Geiser M, Im Hof V, Lee MM, and Schuerch S: Airway surfactant, a primary defense barrier: mechanical and immunological aspects. J Aerosol Med. 1996;9:163-181.
8. Brand P, Rieger C, Beinert T, and Heyder J: Aerosol derived airway morphometry in healthy subjects. Eur Respir J. 1995;8:1639-1646.
9. Stahlhofen W, Scheuch G, and Bailey MR: Investigations of retention of inhaled particles in the human bronchial tree. Radiat Protein Dosim. 1995;60:311-319.
10. Scheuch G, Gebhart J, Heigwer G, and Stahlhofen W: New device for human inhalation studies with small aerosol boluses. J Aerosol Sci. 1989;20:1293-1296.
11. Lippmann M, Yeates DB, and Albert RE: Deposition, retention, and clearance of inhaled particles. Br J Ind Med. 1980;37:337-362.
12. Stahlhofen W, Gebhart J, and Heyder J: Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. AIHA J. 1980;41:385-398.
13. Weibel ER, and Gil J: Electron microscopic demonstration of an extracellular duplex lining layer of alveoli. Respir Physiol. 1968;4:42-57.
14. Schurch S, Gehr P, Im Hof V, Geiser M, and Green F: Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol. 1990;80:17-32.
15. Gehr P, Geiser M, Im Hof V, Schurch S, Waber U, and Baumann M: Surfactant and inhaled particles in the conducting airways: structural, stereological, and biophysical aspects. Microsc Res Tech. 1993;26:423-436.
16. Groneberg DA, Witt C, Wagner U, Chung KF, and Fischer A: Fundamentals of pulmonary drug delivery. Respir Med. 2003;97:382-387.
17. Stahlhofen W, Gebhart J, Rudolf G, and Scheuch G: Measurement of lung clearance with pulses of radioactivelylabelled aerosols. J Aerosol Sci. 1986;17:333-336.
18. Moeller W, Haeinger K, Winkler-Heil R, Stahlhofen W, Meyer T, Hofmann W, and Heyder J: Mucociliary and longterm particle clearance in the airways of healthy nonsmoker subjects. J Appl Physiol. 2004;97:2200-2206.
19. Stahlhofen W, Gebhart J, Rudolf G, Scheuch G, and Philipson K: Clearance from the human airways of particles of different sizes deposited from inhaled aerosol boli. In: Schikarski W (ed.): Aerosols: Formation and Reactivity. Pergamon, Oxford, UK; pp. 192-196, 1986.
20. Stahlhofen W, Koebrich R, Rudolf G, and Scheuch G: Shortterm and long-term clearance of particles from the upper human respiratory tract as function of particle size. J Aerosol Sci. 1990;21:407-410.
21. Scheuch G, and Stahlhofen W: Particle deposition of inhaled aerosol boluses in the upper human airways. J Aerosol Sci. 1987;18:725-727.
22. ICRP: Human Respiratory Tract Model for Radiological Protection. ICRP Publication 66, UK; 1994.
23. Smith JRH, Bailey MR, Etherington G, Shutt AL, and Youngman MJ: Effect of particle size on slow particle clearance from the bronchial tree. Exp Lung Res. 2008;34: 287-312.
24. Gerber V, Gehr P, Straub R, Frenz M, King M, and Im Hof V: Mucus quality on horse tracheal epithelium: microscopic grading based on transparency. Respir Physiol. 1997;107: 67-74.
25. Champion JA, and Mitragotri S: Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009;26: 244-249.
26. Henning A, Schneider M, Bur M, Blank F, Gehr P, and Lehr CM: Embryonic chicken trachea as a new in vitro model for the investigation of mucociliary particle clearance in the airways. AAPS PharmSciTech. 2008;9:521-527.
27. Agnihotri SA, Mallikarjuna NN, and Aminabhavi TM: Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100:5-28.
28. Lehr CM: Lectin-mediated drug delivery: The second generation of bioadhesives. J Control Release. 2000;65:19-29.
29. Rabea EI, Badawy MET, Stevens CV, Smagghe G, and Steurbaut W: Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules. 2003;4:1457-1465.
30. Neuss S, Apel C, Buttler P, Denecke B, Dhanasingh A, Ding X, Grafahrend D, Groger A, Hemmrich K, Herr A, Jahnen- Dechent W, Mastitskaya S, Perez-Bouza A, Rosewick S, Salber J, Woeltje M, and Zenke M: Assessment of stem cell=biomaterial combinations for stem cell-based tissue engineering. Biomaterials. 2008;29:302-313.
31. Grafahrend D, Calvet JL, Klinkhammer K, Salber J, Dalton PD, Möller M, and Klee D: Control of protein adsorption on functionalized electrospun fibers. Biotechnol Bioeng. 2008;101:609-621.
32. Rytting E, Nguyen J, Wang X, and Kissel T: Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5:629-639.
33. Wang X, Xie X, Cai C, Rytting E, Steele T, and Kissel T: Biodegradable Branched Polyesters Poly(vinyl sulfonatecovinyl alcohol)-graft-Poly(D,L-lactic- coglycolic acid) as a negatively-charged polyelectrolyte platform for drug delivery: synthesis and characterization. Macromolecules. 2008; 41:2791-2799.
34. Ravi Kumar MNV, Bakowsky U, and Lehr CM: Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771-1777.
35. Nafee N, Taetz S, Schneider M, Schaefer UF, and Lehr CM: Chitosan-coated PLGA nanoparticles for DNA=RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3:173-183.
36. Ganachaud F, and Katz JL: Nanoparticles and nanocapsules created using the ouzo effect: spontaneous emulsification as an alternative to ultrasonic and high-shear devices. Chem Phys Chem. 2005;6:209-216.
37. Horisawa E, Kubota K, Tuboi I, Sato K, Yamamoto H, Takeuchi H, and Kawashima Y: Size-dependency of DLlactide= glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res. 2002;19:132-139.
38. Weiss B, Schaefer UF, Zapp J, Lamprecht A, Stallmach A, and Lehr CM: Nanoparticles made of fluorescence-labelled poly(L-lactide-co-glycolide): Preparation, stability, and biocompatibility. J Nanosci Nanotechnol. 2006;6:3048-3056.
39. Blank F, Rothen-Rutishauser BM, Schurch S, and Gehr P: An optimized in vitro model of the respiratory tract wall to study particle cell interactions. J Aerosol Med. 2006;19: 392-405.
40. Scheuch G, Stahlhofen W, and Heyder J: An approach to deposition and clearance measurements in human airways. J Aerosol Med. 1996;9:35-41.
41. Fuloria M, and Rubin BK: Evaluating the efficacy of mucoactive aerosol therapy. Respir Care. 2000;45:868-873.
42. King M: Effects of particles on mucus and mucociliary clearance. In: Gehr P, and Heyder J (eds.): Particle-Lung Interactions. Lenfant series vol.143. Marcel Dekker Inc., New York; pp. 521-532, 2000.
43. Verdugo P: Goblet cells secretion and mucogenesis. Annu Rev Physiol. 1990;52:157-176.
44. Lethem MI: The role of tracheobronchial mucus in drug administration to the airways. Adv Drug Deliv Rev. 1993;11:271-298.
45. Cone RA: Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61:75-85.
46. van As A: Pulmonary airway defence mechanisms: an appreciation of integrated mucociliary activity. Eur J Respir Dis Suppl. 1980;111:21-24.3
47. Matsui H, Randell SH, Peretti SW, Davis CW, and Boucher RC: Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest. 1998;102:1125-1131.
48. Lay JC, Alexis NE, Zeman KL, Peden DB, and Bennett WD: In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers. Thorax. 2009;64:313-320.
49. Champion JA, Walker A, and Mitragotri S: Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 2008;25:1815-1821.
50. Gehr P, Schuerch S, Berthiaume Y, Im Hof V, and Geiser M: Particle retention in airways by surfactant. J Aerosol Med. 1990;3:27-43.
51. Bailey MR, Ansoborlo E, Guilmette RA, and Paquet F: Updating the ICRP human respiratory tract model. Radiat Protein Dosim. 2007;127:31-34.
52. ICRP: Human respiratory tract model for radiological protection. Ann ICRP. 1994;24:1-120.
53. Lai SK, OHanlon DE, Harrold S, Man ST, Wang YY, Cone R, and Hanes J: Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA. 2007;104:1482-1487.
54. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, DAngelo J, and Couvreur P: Stealth(-) PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 1999;60:121-128.
55. Gref R, Lueck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, and Mueller RH: "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18:301-313.
56. Sogias IA, Williams AC, and Khutoryanskiy VV: Why is chitosan mucoadhesive? Biomacromolecules. 2008;9:1837-1842.
57. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, and Evans CM: Airway mucus: from production to secretion. Am J Respir Cell Mol Biol. 2006;34:527-536.
58. Shah AJ, and Donovan MD: Rheological characterization of neutral and anionic polysaccharides with reduced mucociliary transport rates. AAPS PharmSciTech. 2007;8:32.
59. Shah AJ, and Donovan MD: Formulating gels for decreased mucociliary transport using rheologic properties: polyacrylic acids. AAPS PharmSciTech. 2007;8.
60. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, and Linse S: Understanding the nanoparticle-protein corona using methods to quntify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA. 2007;104:2050-2055.
61. Roecker C, Poetzl M, Zhang F, Parak WJ, and Nienhaus GU: A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat Nanotechnol. 2009;4:577-580